Danaher (NYSE:DHR) issued an update on its FY 2019 earnings guidance on Thursday morning. The company provided EPS guidance of $4.72-4.80 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.79. Danaher also updated its FY19 guidance to $4.72-4.80 EPS.
Shares of NYSE DHR traded up $0.34 during trading on Friday, hitting $131.68. 1,587,625 shares of the company traded hands, compared to its average volume of 2,622,772. Danaher has a 1 year low of $94.59 and a 1 year high of $134.67. The stock has a market capitalization of $94.03 billion, a PE ratio of 29.13, a P/E/G ratio of 2.54 and a beta of 1.02. The company has a quick ratio of 1.74, a current ratio of 2.18 and a debt-to-equity ratio of 0.32.
Danaher (NYSE:DHR) last announced its quarterly earnings results on Thursday, April 18th. The conglomerate reported $1.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.06. Danaher had a net margin of 12.04% and a return on equity of 11.61%. The firm had revenue of $4.88 billion during the quarter, compared to analysts’ expectations of $4.80 billion. During the same period in the prior year, the company earned $0.99 EPS. The firm’s revenue was up 3.9% on a year-over-year basis. Equities research analysts expect that Danaher will post 4.77 EPS for the current fiscal year.
A number of analysts recently weighed in on DHR shares. Janney Montgomery Scott raised shares of Danaher from a neutral rating to a buy rating in a research report on Monday, February 25th. UBS Group upped their price target on shares of Danaher from $125.00 to $144.00 and gave the stock a buy rating in a research report on Tuesday, February 26th. Deutsche Bank upped their price objective on shares of Danaher to $130.00 and gave the company a buy rating in a research report on Tuesday, February 26th. Jefferies Financial Group upped their price objective on shares of Danaher to $140.00 and gave the company a buy rating in a research report on Tuesday, February 26th. Finally, Needham & Company LLC reissued a buy rating and issued a $138.00 price objective (up from $114.00) on shares of Danaher in a research report on Thursday, February 28th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $131.75.
In other news, insider Rainer Blair sold 37,859 shares of the company’s stock in a transaction dated Wednesday, February 27th. The shares were sold at an average price of $127.45, for a total value of $4,825,129.55. Following the sale, the insider now owns 32,661 shares in the company, valued at approximately $4,162,644.45. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Walter G. Lohr sold 10,578 shares of the company’s stock in a transaction dated Wednesday, February 27th. The shares were sold at an average price of $126.85, for a total transaction of $1,341,819.30. Following the completion of the sale, the director now owns 20,691 shares in the company, valued at approximately $2,624,653.35. The disclosure for this sale can be found here. In the last 90 days, insiders sold 424,761 shares of company stock worth $54,983,097. Company insiders own 11.40% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/05/11/danaher-dhr-issues-fy-2019-earnings-guidance.html.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Recommended Story: Why is total return important?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.